Specifically, the American Diabetes Association [4] suggests to consider use of a SGLT-2 inhibitor in T2D patients with an estimated glomerular filtration rate ≥ 30 mL/min/1.73 m2 and particularly in those with > 300 mg/g albuminuria to reduce risk of diabetic kidney disease progression, cardiovascular events, or both. Here, SLC5A2 is linked to type 2 diabetes mellitus.